Tag: eosinophilic asthma market size

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Major Innovations Are Driving the Accelerated Growth of the Eosinophilic Asthma Market?

The rising smoking habits are expected to propel the growth of the eosinophilic asthma market. Smoking, despite increasing awareness of its health risks, remains a significant contributor to respiratory diseases like eosinophilic asthma, a severe form of asthma that involves inflammation of the airways. Eosinophilic asthma treatments help reduce airway inflammation and improve lung function, which may also support smoking cessation efforts. December 2023 data from the National Health Service reported a rise in hospital admissions related to smoking, with 408,700 admissions in 2022-2023, an increase of 4.8% from the previous year. The correlation between smoking habits and respiratory diseases like eosinophilic asthma is fueling the market’s growth.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

#What Are the Key Projections for the CAGR of the Eosinophilic Asthma Market From 2025 to 2034?

The eosinophilic asthma market has grown rapidly, increasing from $2.69 billion in 2024 to $3.17 billion in 2025 at a CAGR of 17.7%. The market’s historical growth drivers include rising pollution levels, weakened immunity in populations, an increasing prevalence of eosinophilic asthma, a growing number of allergens and respiratory conditions, higher healthcare expenditures, and rising investments in R&D.

The eosinophilic asthma market is forecasted to grow rapidly, reaching $6.01 billion by 2029 at a CAGR of 17.4%. Factors contributing to this growth include the increasing prevalence of respiratory diseases, higher awareness and diagnosis rates, expanded therapeutic indications for monoclonal antibodies, rising investment in healthcare infrastructure, and a shift toward personalized medicine approaches. Key trends include the development of targeted biologics, enhanced diagnostic tools, personalized treatment strategies, improved drug delivery systems, the integration of digital health technologies, and expanded clinical trials for innovative therapies.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21184

What Are the Most Significant Market Trends Transforming theEosinophilic Asthma Market?

Major companies operating in the eosinophilic asthma market are developing innovative treatments to target specific immune pathways, reduce inflammation, and improve patient outcomes through personalized treatment options. One such treatment is the use of monoclonal antibodies, which are laboratory-made molecules designed to mimic the immune system’s natural ability to fight pathogens. These antibodies are created by fusing an antibody-producing cell with a cancer cell, enabling the production of large quantities of identical antibodies. For instance, in August 2024, AstraZeneca plc, a UK-based biopharmaceutical company, received approval from China’s National Medical Products Association for Fasenra to treat severe eosinophilic asthma. Fasenra works by binding to the IL-5 receptor on eosinophils, reducing their levels in blood and tissues, thereby alleviating inflammation and asthma symptoms. The treatment regimen involves an initial loading phase, followed by maintenance doses every 8 weeks after the first three doses.

What Are the Top Market Players Propelling the Growth of theEosinophilic Asthma Industry?

Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

Which Primary Segments of the Eosinophilic Asthma Market Are Driving Growth and Industry Transformations?

The eosinophilic asthma market covered in this report is segmented –

1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=21184&type=smp

Which Regions Are Key Players in the Growth of the #What Major Innovations Are Driving the Accelerated Growth of the Eosinophilic Asthma Market?# Market?

North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Eosinophilic Asthma Market 2025, By The Business Research Company:

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Metastatic Breast Cancer Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metastatic-breast-cancer-treatment-global-market-report

Global Cell And Gene Therapy Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/cell-and-gene-therapy-market-

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What fueled the previous growth in the eosinophilic asthma market?

There has been a significant expansion in the size of the eosinophilic asthma market in the past few years. The market, valued at $2.69 billion in 2024, is forecasted to rise to $3.17 billion in 2025, growing at a compound annual growth rate (CAGR) of 17.7%. Factors that have led to this growth in the previous years include escalated pollution, a decline in people’s immunity, an increase in the occurrence of eosinophilic asthma, a surge in the incidence of allergens and respiratory issues, heightened healthcare spending, and an increase in research and development initiatives.

What will be the eosinophilic asthma market size in the future?

Rapid expansion is anticipated in the eosinophilic asthma market in the upcoming years, with its size predicted to hit $6.01 billion in 2029, increasing at a compound annual growth rate (CAGR) of 17.4%. The forecast period’s growth can be linked to the escalating occurrence of respiratory illnesses, increased awareness and diagnosis frequencies, wider application of monoclonal antibodies in therapy, significant investment in healthcare infrastructure, and the advent of personalized medicine approaches. The forecast period is also expected to witness trends such as the creation of targeted biologics, enhanced diagnostic tools, personalized treatment strategies, advanced drug delivery systems, the incorporation of digital health technologies, and the broadening of clinical trials for new therapies.

Get your eosinophilic asthma market report here!

https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

What main drivers are fueling expansion in the eosinophilic asthma market?

The escalating rates of smoking habits are projected to spur the expansion of the eosinophilic asthma market in the future. Such habits pertain to regular routines or patterns related to the use of tobacco, which includes frequency, context, and duration of smoking. These habits are often impacted by psychological, social, and environmental elements. Factors such as heightened stress levels, strategic advertising by tobacco corporations, lack of health risk awareness, and social acceptance of smoking in particular cultures are contributing to the increment in smoking habits. Treatments for eosinophilic asthma assist in minimizing inflammation in the airways and enhancing lung function. This can promote quitting smoking by easing the respiratory complications that frequently prompt patients to persist in smoking. For example, as reported by the National Health Service, a UK-based government unit, hospital admissions due to smoking increased by 4.8%, from 389,800 in 2021–22 to around 408,700 in 2022–23. Thus, the upsurge in smoking rates propels the eosinophilic asthma market.

What key areas define the segmentation of the global eosinophilic asthma market?

The eosinophilic asthma market covered in this report is segmented –

1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

Who are the dominant players expanding their reach in the eosinophilic asthma market?

Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A.

What are the key trends shaping the future of the eosinophilic asthma market?

Key eosinophilic asthma market players are focusing on the development of novel drugs that specifically target immune pathways, minimize inflammation, and enhance patient results via customised treatment methods. Monoclonal antibodies, a kind of molecule synthesized in labs, replicate the immune system’s capacity to combat harmful pathogens like bacteria and viruses. These are generated through a fusion process of a specific antibody-generating cell and a cancer cell, facilitating the production of large volumes of identical antibodies. For example, in August 2024, the UK’s biopharmaceutical firm, AstraZeneca plc, announced that China’s National Medical Products Association has approved Fasenra for treating severe eosinophilic asthma. This disease is marked by elevated eosinophil levels, causing inflammation and worsening asthma symptoms. Fasenra, a monoclonal antibody, targets and eliminates eosinophils via a unique mechanism and boosts the immune system’s capability by binding to the IL-5 receptor on eosinophils, thus lowering eosinophil levels in blood and tissues. The dosage regimen commences with an initial loading phase, after which maintenance doses are administered. Injections are typically given every four weeks for the initial three dosages, and every eight weeks after that.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21184

Which regions are emerging as leaders in the eosinophilic asthma market?

North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Metastatic Breast Cancer Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metastatic-breast-cancer-treatment-global-market-report

Global Cell And Gene Therapy Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/cell-and-gene-therapy-market-

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What CAGR is Anticipated for the Eosinophilic Asthma Market During the Forecast Period, and Why?

In recent times, the eosinophilic asthma market has experienced swift expansion. Projections indicate that its value will rise from $2.69 billion in 2024 to $3.17 billion in 2025, marking a compound annual growth rate (CAGR) of 17.7%. This significant growth during the historic period can be credited to factors like heightened pollution, compromised immunity among the general population, increased incidences of eosinophilic asthma and prevalence of allergens and respiratory conditions, growth in healthcare spending, and a surge in R&D endeavors.

The market for eosinophilic asthma is predicted to experience substantial growth in the forthcoming years, ballooning to $6.01 billion by 2029 with a compound annual growth rate (CAGR) of 17.4%. The surge in the forecast period can be linked to the escalating incidence of respiratory illnesses, increased recognition and diagnostic rates, a broader range of therapeutic indications for monoclonal antibodies, heightened spending in healthcare infrastructure, and an uptick in personalised medical practices. The forecast period will be characterised by outstanding trends like the creation of targeted biologics, enhanced diagnostic instruments, customised treatment strategies, advanced drug delivery systems, incorporation of cyber health innovations, and broadened clinical trials for ground-breaking therapies.

What External and Internal Drivers Are Contributing to the Growth of the Eosinophilic Asthma Market’s Growth?

The escalating trend of smoking practices is anticipated to drive the expansion of the eosinophilic asthma market. These practices entail habitual or standard usage of tobacco products, dictated by the frequency, scenario, and length of smoking, often shaped by psychological, societal, and environmental aspects. The surge in smoking practices is attributed to elements like heightened stress levels, strategic advertising by tobacco corporations, lack of knowledge about potential health hazards, and the social normalization of smoking in certain communities. Treatment for eosinophilic asthma helps to lessen inflammation of the airways and enhance lung function, thereby aiding in smoking cessation by addressing the respiratory complications that primarily prompt individuals to persist with smoking. For instance, the National Health Service, a state department based in the UK, reported in December 2023 that there were approximately 408,700 hospital admissions owing to smoking in the 2022-23 timeframe, up from 389,800 in 2021-22, implying a growth of 4.8%. Hence, the increase in smoking rates propels the eosinophilic asthma market.

Get Your Free Sample of the Global Eosinophilic Asthma Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

Which Companies Are Poised to Shape the Future of the Eosinophilic Asthma Market?

Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A.

What Are the Latest Innovations and Trends Influencing the Eosinophilic Asthma Market?

Dominant businesses in the eosinophilic asthma market are focusing on the development of cutting-edge medications that target specific immune pathways. These drugs aim to decrease inflammation and enhance patient outcomes through individualized treatment plans. One type of these lab-created molecules is a monoclonal antibody, which emulates the immune system’s ability to combat harmful pathogens such as viruses and bacteria. The production of these antibodies involves the fusion of a specific antibody-producing cell with a cancer cell, leading to the creation of vast quantities of identical antibodies. As an example, in August 2024, AstraZeneca plc, a biopharmaceutical firm based in the UK, announced that Fasenra was approved by the National Medical Products Association, a government agency in China, for the treatment of severe eosinophilic asthma. This condition is marked by high eosinophil levels, leading to inflammation and exacerbation of asthma symptoms. Fasenra, a monoclonal antibody, targets and diminishes eosinophils using a unique mechanism. It boosts the immune system by adhering to the IL-5 receptor on eosinophils, thereby reducing eosinophil levels within the blood and tissues. The dosage schedule requires an initial loading phase, followed by maintenance doses. Typically, patients receive injections every four weeks for the initial three doses, followed by every eight weeks after.

Get Instant Access to the Global Eosinophilic Asthma Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

Which Industry Segments Are Leading the Development and Expansion of the Eosinophilic Asthma Market?

The eosinophilic asthma market covered in this report is segmented –

1) By Disease: Severe Eoisnophilic Asthma, Mild To Moderate Eosinophilic Asthma

2) By Treatment: Biologics, Bronchodilators, Corticosteroids, Immunomodulators, Other Treatments

3) By End User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma, Late-Onset Eosinophilic Asthma

2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma, Intermittent Eosinophilic Asthma

What Regions Are Contributing Significantly to the Growth of the Eosinophilic Asthma Market?

North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

How Is the Scope and Reach of the Eosinophilic Asthma Market Defined?

Eosinophilic asthma is a form of asthma where high eosinophil counts, a specific white blood cell type, cause airway inflammation. This condition results in severe symptoms such as breathing issues and recurring flare-ups, with limited effectiveness from standard treatments such as inhaled steroids.

Browse Through More Similar Reports By The Business Research Company:

Breast Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report

Metastatic Breast Cancer Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metastatic-breast-cancer-treatment-global-market-report

Global Cell And Gene Therapy Opportunities And Strategies Global Market Report 2025

https://thebusinessresearchcompany.com/report/cell-and-gene-therapy-market-

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: